High S100B Levels Predict Antidepressant Response in Patients With Major Depression Even When Considering Inflammatory and Metabolic Markers
dc.contributor.author | Navinés, Ricard | |
dc.contributor.author | Oriolo, Giovanni | |
dc.contributor.author | Horrillo Furundarena, Igor ![]() | |
dc.contributor.author | Cavero, Myriam ![]() | |
dc.contributor.author | Aouizerate, Bruno | |
dc.contributor.author | Schaefer, Martin | |
dc.contributor.author | Capuron, Lucile ![]() | |
dc.contributor.author | Meana Martínez, José Javier ![]() | |
dc.contributor.author | Martín Santos, Rocío | |
dc.date.accessioned | 2022-08-02T11:59:56Z | |
dc.date.available | 2022-08-02T11:59:56Z | |
dc.date.issued | 2022-06 | |
dc.identifier.citation | International Journal of Neuropsychopharmacology 25(6) : 468-478 (2022) | es_ES |
dc.identifier.issn | 1461-1457 | |
dc.identifier.issn | 1469-5111 | |
dc.identifier.uri | http://hdl.handle.net/10810/57158 | |
dc.description.abstract | [EN] Background The relationship between antidepressant response and glial, inflammatory, and metabolic markers is poorly understood in depression. This study assessed the ability of biological markers to predict antidepressant response in major depressive disorder (MDD). Methods We included 31 MDD outpatients treated with escitalopram or sertraline for 8 consecutive weeks. The Montgomery-angstrom sberg Depression Rating Scale (MADRS) was administered at baseline and at week 4 and 8 of treatment. Concomitantly, blood samples were collected for the determination of serum S100B, C-reactive protein (CRP), and high-density lipoprotein cholesterol (HDL)-C levels. Treatment response was defined as >= 50% improvement in the MADRS score from baseline to either week 4 or 8. Variables associated with treatment response were included in a linear regression model as predictors of treatment response. Results Twenty-seven patients (87%) completed 8 weeks of treatment; 74% and 63% were responders at week 4 and 8, respectively. High S100B and low HDL-C levels at baseline were associated with better treatment response at both time points. Low CRP levels were correlated with better response at week 4. Multivariate analysis showed that high baseline S100B levels and low baseline HDL-C levels were good predictors of treatment response at week 4 (R(2 = )0.457, P = .001), while S100B was at week 8 (R-2 = 0.239, P = .011). Importantly, baseline S100B and HDL-C levels were not associated with depression severity and did not change over time with clinical improvement. Conclusions Serum S100B levels appear to be a useful biomarker of antidepressant response in MDD even when considering inflammatory and metabolic markers | es_ES |
dc.description.sponsorship | We thank the consolidated research groups SGR2017/1798 (RMS) and the Centre for Biomedical Research in Mental Health Network (CIBERSAM), Spain for their support. This work was supported by an "Emili Letang Premi Final de Residencia (2017)" grant (G.O.) from Fundacio Clinic, Barcelona, Spain. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Oxford University | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es/ | * |
dc.subject | S100B protein | es_ES |
dc.subject | reactive-C protein | es_ES |
dc.subject | HDL-cholesterol | es_ES |
dc.subject | major depression | es_ES |
dc.title | High S100B Levels Predict Antidepressant Response in Patients With Major Depression Even When Considering Inflammatory and Metabolic Markers | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.holder | © The Author(s) 2022. Published by Oxford University Press on behalf of CINP. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. | es_ES |
dc.rights.holder | Attribution-NonCommercial 3.0 Spain | * |
dc.relation.publisherversion | https://academic.oup.com/ijnp/article/25/6/468/6530347?login=true | es_ES |
dc.identifier.doi | 10.1093/ijnp/pyac016 | |
dc.departamentoes | Farmacología | es_ES |
dc.departamentoeu | Farmakologia | es_ES |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as © The Author(s) 2022. Published by Oxford University Press on behalf of CINP.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.